The CRISPR Patent Battle: Implications for Downstream Innovation in Gene Editing

March 21, 2017
Engelberg Center on Innovation Law & Policy

The CRISPR Patent Battle: Implications for Downstream Innovation in Gene Editing

Four expert panelists discuss the CRISPR technology and key issues in the recent patent litigation between two universities that developed the technology via federal research grant funding. In particular, they offer their perspectives on how the recent ruling may affect the short-term strategy of companies seeking to innovate using the CRISPR platform, and the longer-term implications of the respective universities’ CRISPR licensing strategies for downstream innovation using the CRISPR platform.

Panelists:
Professor Lisa Larrimore Ouellette (Stanford Law School)
Professor Jacob Sherkow (New York Law School)
Bruce Wexler (Partner, Chair of the Life Sciences Industry Practice Group, Paul Hastings)
Abram Goldfinger (Executive Director of the Office of Industrial Liaison at New York University)

Moderator:
Anne Hassett (Executive Director of the NYU Law Engelberg Center on Innovation Law & Policy)